Ningbo Menovo Pharmaceutical Co., Ltd.
Símbolo: 603538.SS
SHH
14.58
CNYPrecio de mercado actual
-165.8310
Ratio PER
-26.5330
Ratio PEG
3.09B
Capitalización MRK
- 0.01%
Rendimiento DIV
Ningbo Menovo Pharmaceutical Co., Ltd. (603538-SS) Estados Financieros
Balance de situación
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3108.99 | 724.7 | 1009.3 | 793.2 | |||||||||||||
balance-sheet.row.short-term-investments | 961.42 | 268.6 | 217.4 | 371.4 | |||||||||||||
balance-sheet.row.net-receivables | 1197.96 | 320.7 | 231.5 | 266.2 | |||||||||||||
balance-sheet.row.inventory | 2630.14 | 612.6 | 594.4 | 579.7 | |||||||||||||
balance-sheet.row.other-current-assets | 198.07 | 50.3 | 59.2 | 63.4 | |||||||||||||
balance-sheet.row.total-current-assets | 7254.8 | 1759.4 | 1894.4 | 1702.4 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 7582.87 | 1900.3 | 1801.9 | 1614.7 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 22.7 | |||||||||||||
balance-sheet.row.intangible-assets | 802.34 | 206.2 | 172.5 | 201.7 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 802.34 | 206.2 | 172.5 | 224.4 | |||||||||||||
balance-sheet.row.long-term-investments | 832.39 | 315.3 | 82.7 | -51.8 | |||||||||||||
balance-sheet.row.tax-assets | 335.17 | 42.7 | 123.1 | 33.3 | |||||||||||||
balance-sheet.row.other-non-current-assets | 942.78 | 199.6 | 344.8 | 478.5 | |||||||||||||
balance-sheet.row.total-non-current-assets | 10495.55 | 2664.1 | 2525.1 | 2299.1 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 17750.35 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.account-payables | 2040.98 | 553.7 | 499.3 | 389.1 | |||||||||||||
balance-sheet.row.short-term-debt | 2165.58 | 542.8 | 497 | 505 | |||||||||||||
balance-sheet.row.tax-payables | 115.34 | 25.5 | 72.1 | 34.6 | |||||||||||||
balance-sheet.row.long-term-debt-total | 3022.3 | 759.6 | 705.6 | 755.3 | |||||||||||||
Deferred Revenue Non Current | 330.02 | 81.5 | 70.6 | 48.7 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 220.86 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 8.2 | 2 | 171 | 3.9 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3592.57 | 859.6 | 884 | 876.2 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 102.15 | 15.7 | 30.3 | 28 | |||||||||||||
balance-sheet.row.total-liab | 8956.27 | 2237.8 | 2246.2 | 2023 | |||||||||||||
balance-sheet.row.preferred-stock | 72.59 | 36.3 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 853.57 | 213.4 | 213.4 | 151.3 | |||||||||||||
balance-sheet.row.retained-earnings | 4918.84 | 1210.6 | 1234.3 | 937.4 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 986.88 | 75.6 | 101.4 | 77.6 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1595.49 | 560.4 | 535.9 | 585.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 8427.36 | 2096.3 | 2085 | 1751.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 17750.35 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.minority-interest | 366.72 | 89.4 | 88.3 | 227 | |||||||||||||
balance-sheet.row.total-equity | 8794.08 | 2185.7 | 2173.2 | 1978.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 17750.35 | - | - | - | |||||||||||||
Total Investments | 1259.87 | 315.3 | 300.1 | 319.6 | |||||||||||||
balance-sheet.row.total-debt | 5187.88 | 1302.5 | 1202.6 | 1260.4 | |||||||||||||
balance-sheet.row.net-debt | 3040.31 | 846.4 | 410.7 | 838.6 |
Estado de tesorería
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -17.82 | 367.6 | 158.1 | 173.1 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 90.3 | 101.8 | 98.9 | 85 | ||||||||||||
cash-flows.row.deferred-income-tax | -13.64 | -40.2 | -21 | 18.4 | ||||||||||||
cash-flows.row.stock-based-compensation | 11.27 | 24.7 | 5.3 | 10.9 | ||||||||||||
cash-flows.row.change-in-working-capital | -124.06 | -85.4 | -62.2 | -2.8 | ||||||||||||
cash-flows.row.account-receivables | -98.84 | -213.6 | -50.9 | -28.2 | ||||||||||||
cash-flows.row.inventory | -49.56 | -183 | -124.7 | -83 | ||||||||||||
cash-flows.row.account-payables | 0 | 351.4 | 134.4 | 63.3 | ||||||||||||
cash-flows.row.other-working-capital | 24.33 | -40.2 | -21 | 45.1 | ||||||||||||
cash-flows.row.other-non-cash-items | 36.58 | -91.4 | 41.5 | -32.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -28.65 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -142.43 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.acquisitions-net | 0.3 | 487.9 | -47.1 | 0.5 | ||||||||||||
cash-flows.row.purchases-of-investments | -994.74 | -713.9 | -1640.5 | -865 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 853.67 | 902.5 | 1562.2 | 693.5 | ||||||||||||
cash-flows.row.other-investing-activites | -116.67 | -54.6 | 52 | 3.8 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -247.84 | 50.3 | -603.3 | -479 | ||||||||||||
cash-flows.row.debt-repayment | -399.52 | -749.5 | -788.1 | -802.5 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0.2 | 0.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | -0.5 | ||||||||||||
cash-flows.row.dividends-paid | -60.49 | -50 | -13.8 | -41 | ||||||||||||
cash-flows.row.other-financing-activites | 446.21 | 621.1 | 1385.1 | 981.9 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 60.68 | -178.5 | 583.1 | 138.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -22.05 | 14.6 | -2.3 | -2 | ||||||||||||
cash-flows.row.net-change-in-cash | -237.86 | 163.4 | 198.2 | -91 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 1234.49 | 537 | 373.6 | 174.5 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1472.34 | 373.6 | 175.4 | 265.5 | ||||||||||||
cash-flows.row.operating-cash-flow | -28.65 | 277 | 220.6 | 251.6 | ||||||||||||
cash-flows.row.capital-expenditure | -142.43 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.free-cash-flow | -171.08 | -294.7 | -309.3 | -60.1 |
Fila de la Cuenta de Resultados
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1232.95 | 1216.5 | 1457 | 1258.1 | |||||||||||||
income-statement-row.row.cost-of-revenue | 839.39 | 840.9 | 872.8 | 788.9 | |||||||||||||
income-statement-row.row.gross-profit | 393.56 | 375.6 | 584.2 | 469.2 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 99.54 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 57.01 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 52.13 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | -11.95 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.operating-expenses | 305.9 | 291.2 | 341.4 | 281 | |||||||||||||
income-statement-row.row.cost-and-expenses | 1145.29 | 1132.1 | 1214.2 | 1069.9 | |||||||||||||
income-statement-row.row.interest-income | 6.12 | 5.5 | 5.7 | 2.2 | |||||||||||||
income-statement-row.row.interest-expense | 30.96 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 52.13 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -77.38 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | -11.95 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.total-operating-expenses | -77.38 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.interest-expense | 30.96 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 125.92 | 118.5 | 128.3 | 124.1 | |||||||||||||
income-statement-row.row.ebitda-caps | 59.17 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -15.63 | 18.7 | 405.3 | 187.9 | |||||||||||||
income-statement-row.row.income-before-tax | -27.57 | 8 | 384.2 | 180.3 | |||||||||||||
income-statement-row.row.income-tax-expense | -13.31 | -8.2 | 16.5 | 22.2 | |||||||||||||
income-statement-row.row.net-income | -17.82 | 11.6 | 338.9 | 142.5 |
Preguntas frecuentes
Cuánto es Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) activos totales?
Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) los activos totales son 4423515920.000.
¿Cuáles son los ingresos anuales de la empresa?
Los ingresos anuales son 550731997.000.
¿Cuál es el margen de beneficios de la empresa?
El margen de beneficios de la empresa es 0.319.
¿Qué es el flujo de caja libre de la empresa?
El flujo de caja libre es -0.853.
¿Cuál es el margen de beneficio neto de la empresa?
El margen de beneficio neto es -0.014.
¿Cuáles son los ingresos totales de la empresa?
Los ingresos totales son -0.013.
¿Qué es Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) beneficio neto (ingresos netos)?
El beneficio neto (ingresos netos) es 11585592.000.
¿Cuál es la deuda total de la empresa?
La deuda total es 1302458461.000.
¿Cuál es la cifra de gastos de explotación?
Los gastos de explotación son 291175048.000.
¿Cuál es la cifra de tesorería de la empresa?
La tesorería de la empresa es 351891745.000.